SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

DRTS

Alpha Tau Medical Ltd.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The widening loss is concerning, but the $76.9M cash runway supports ongoing clinical and commercial development. Traders should monitor upcoming milestones: completion of U.S. skin cancer trial recruitment (Q1 2026), pancreatic trial enrollment (Q2 2026), and initial GBM safety readout (Q2 2026). Positive data or accelerated approvals could drive upside.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.84
T+0 close · Mar 9, 2026 · via day close
Latest settled
+54.68%
T+60 · $10.58
Vs SPY
+42.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $6.84entry
  2. T+1 · 8mo ago +2.92%α +3.03% · $7.04
  3. T+5 · 8mo ago +9.21%α +10.12% · $7.47
  4. T+20 · 7mo ago +5.26%α +5.42% · $7.20
  5. T+60 · 6mo ago +54.68%α +42.99% · $10.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical reported its 2025 financial results, showing a wider net loss of $42.6 million ($0.53/share) compared to $31.8 million ($0.45/share) in 2024, driven by higher R&D and G&A expenses. Despite the increased loss, the company highlighted significant clinical and regulatory progress, including Japanese marketing approval for head and neck cancer, five U.S. trial approvals, and positive pancreatic cancer data presented at ASCO GI, while ending the year with $76.9 million in cash.

Key Financial Metrics

EPS
$-0.53

Key Facts

  • Net loss widened to $42.6M in 2025 from $31.8M in 2024
  • R&D expenses increased to $32.1M from $27.0M in 2024
  • Cash, cash equivalents, and deposits totaled $76.9M as of Dec 31, 2025
  • Received marketing approval in Japan for head and neck cancer
  • Five U.S. clinical trials approved in parallel, including for prostate and brain cancers
  • Positive pancreatic cancer data: 22% ORR and 81% DCR in 32-patient study
  • First patient treated in U.S. recurrent glioblastoma trial
  • Submitted first module of PMA application to FDA for skin cancer

Financial Impact

Net loss increased by 34% YoY to $42.6 million; cash position grew by $14 million to $76.9 million

net lossepscashr_and_d_expense

Risk Factors

  • Continued losses and need for future funding could lead to dilution
  • Clinical trial delays or adverse results could impair development timelines
  • Regulatory setbacks in U.S. or other markets despite Japanese approval

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3252290

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026